1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

03 May 2024
Admin
News Article

Astellas, Poseida Therapeutics Ink Research Collab to Develop Allogeneic Cell Therapies in Oncology

Astellas, Poseida Therapeutics ink research collaboration & license agreement to develop allogeneic cell therapies in oncology

Overview

Astellas Pharma Inc, a pharmaceutical company conducting business in more than 70 countries around the world, and Poseida Therapeutics, a clinical-stage biopharmaceutical company advancing differentiated cell therapies and genetic medicines , announced that Xyphos Biosciences, Inc, (a wholly owned subsidiary of Astellas) and Poseida have entered into a research collaboration and license agreement to develop novel convertibleCAR programmes by combining the innovative cell therapy platforms from each of the companies.

About Poseida

Poseida is advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases.
In oncology, its pipeline includes allogeneic CAR-T cell therapy product candidates for both solid and liquid tumors that address patient populations with high unmet medical need.
Xyphos utilizes a novel and proprietary ACCEL technology platform that uses its convertibleCAR (convertible Chimeric Antigen Receptor) in combination with proprietary MicAbodies to target tumor cells.

Terms of the agreement

Under the terms of the agreement, the companies plan to combine Poseida's proprietary allogeneic CAR-T platform with Xyphos' ACCEL technology to create one Poseida-developed CAR-T construct to form the basis of two convertibleCAR product candidates targeting solid tumors.
Xyphos will reimburse Poseida for costs incurred as part of the research agreement and will be responsible for the development and future commercialization of products generated from the collaboration.
Poseida will receive US$ 50 million upfront plus potential development and sales milestones and contingency payments of up to US$ 550 million in total.
Additionally, Poseida is eligible for up to low double digit tiered royalties as a percentage of net sales.

Words from CEO: Poseida

Kristin Yarema, president and CEO of Poseida, said: ""We are excited to expand our relationship with Astellas, where we share a vision that cutting edge, off the shelf cell therapies can address significant unmet needs of patients with solid tumor malignancies. Today's agreement further reinforces the economic value of Poseida's highly differentiated non-viral technologies and enables development in areas beyond our core pipeline focus. It also highlights Poseida's role as the partner of choice in allogeneic CAR-T.""

Words from CStO: Astellas

Adam Pearson, chief strategy officer (CStO) of Astellas, said: At Astellas, we have a strong commitment to developing novel treatments for patients with cancer and have positioned immuno-oncology as a primary focus of our R&D strategy. By leveraging our extensive expertise, experience in cancer biology and unique technologies, we are focused on reinvigorating the immune system's ability to discover, disarm and destroy cancers in more patients.
By combining the ACCEL platform with Poseida's elegant and cutting-edge genetic editing platforms, we believe the collaboration will bring synergies between the two companies' breakthrough research and will ultimately lead to expansion of Astellas' portfolio and to delivery of innovative CAR-T cell therapies to cancer patients.

Astellas Pharma Inc

Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world.
The company is promoting the focus area approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on biology and modality.

Xyphos Biosciences

Xyphos Biosciences, Inc., located at South San Francisco, California, is a wholly owned subsidiary of Astellas featuring ACCEL technology, a CAR (chimeric antigen receptor) technology platform for immune cell therapies.
Xyphos Biosciences was launched in 2017, and the company was acquired by Astellas Pharma in December of 2019.

Poseida Therapeutics

Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated cell therapies and genetic medicines with the capacity to cure certain cancers and rare diseases.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!